ReviewFrontiers in microbiology2021
Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin.
Review in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Design, Synthesis, and Antibiofilm Efficacy of Ag/Se-Doped CuO-Chitosan Nanocomposites as Potent Antifungal Agents Against Candida albicans.Chemistry & biodiversity · 2026Article
- Nanostructured Hydrogels: A Method to Prevent Biofilms on Implantable Medical Devices.Gels (Basel, Switzerland) · 2026Review
- Monthly dalbavancin dosing for suppressive therapy: a pharmacokinetic estimation analysis and case series.Antimicrobial agents and chemotherapy · 2026Article
- Six-year retrospective analysis of the epidemiology and risk factors of multidrug-resistant bloodstream infections in oncology patients in Jiangxi, China.Microbiology spectrum · 2025Article
- Antibiofilm efficacy of emodin alone or combined with ampicillin against methicillin-resistant Staphylococcus aureus.Scientific reports · 2025Article
- Antimicrobial and Antibiofilm Activity of Auranofin and Its Two Derivatives Bearing Naproxen and Acetylcysteine as Ligands Against Staphylococci.Antibiotics (Basel, Switzerland) · 2025Article
- Dalbavancin-resistantJAC-antimicrobial resistance · 2024Article
- Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections.Clinical pharmacokinetics · 2024Article
- Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience.Antibiotics (Basel, Switzerland) · 2024Article
- Strontium and Zinc Co-Doped Mesoporous Bioactive Glass Nanoparticles for Potential Use in Bone Tissue Engineering Applications.Nanomaterials (Basel, Switzerland) · 2024Article
- Efficacy of sodium hypochlorite in overcoming antimicrobial resistance and eradicating biofilms in clinical pathogens from pressure ulcers.Frontiers in microbiology · 2024Article
- New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.Journal of clinical medicine · 2023Review
- In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement.Antibiotics (Basel, Switzerland) · 2023Article
- Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.Dermatology and therapy · 2023Review
- Chronic Suppressive Antibiotic Treatment for Staphylococcal Bone and Joint Implant-Related Infections.Antibiotics (Basel, Switzerland) · 2023Article
- Liposomes-Based Drug Delivery Systems of Anti-Biofilm Agents to Combat Bacterial Biofilm Formation.Antibiotics (Basel, Switzerland) · 2023Review
- Multifunctional Zn and Ag co-doped bioactive glass nanoparticles for bone therapeutic and regeneration.Scientific reports · 2023Article
- Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
- Article
- Beyond the Risk of Biofilms: An Up-and-Coming Battleground of Bacterial Life and Potential Antibiofilm Agents.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections caused by Gram-positive bacteria are a major public health problem due to their increasing resistance to antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.